AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32413595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications (MEDs)
Number of subjects: 439
Study 35773950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence intervention in Nurse-Family Partnership programme
Number of subjects: 7
Study 33607007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil added to pirfenidone
Number of subjects: 0
Study 33607007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32854838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (S/V)
Number of subjects: 881
Study 32854838 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 881
Study 34378245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzuloparib 50 mg (test preparation)
Number of subjects: 40
Study 34378245 — intervention group
Group type: COMPARATOR
Intervention: Reference preparations (10 mg, 40 mg, 100 mg)
Number of subjects: 40
Study 32111264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 1500
Study 32111264 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo capsules once daily for 6 months
Number of subjects: 1500
Study 33610080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesives (TA)
Number of subjects: 0
Study 33610080 — intervention group
Group type: COMPARATOR
Intervention: Adhesive dressing (AD)
Number of subjects: 0
Study 32552153 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin combination
Number of subjects: 2895
Study 32552153 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin monotherapy
Number of subjects: 2895
Study 32552153 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin monotherapy
Number of subjects: 2895
Study 35979677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 303
Study 35979677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 303
Study 35979677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 303
Study 35979677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 34327687 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference (HC) classified as small normal (5th‐10th percentile)
Number of subjects: 1236
Study 34327687 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference (HC) classified as normal (10th‐90th percentile)
Number of subjects: 1236
Study 34327687 — intervention group
Group type: EXPERIMENTAL
Intervention: Head circumference (HC) classified as large normal (90th‐95th percentile)
Number of subjects: 1236
Study 34327687 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous variable of head circumference (1 cm increase)
Number of subjects: 1236
Study 33112433 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg daily oral avanafil
Number of subjects: 140
Study 33112433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 32925959 — intervention group
Group type: EXPERIMENTAL
Intervention: e-bike
Number of subjects: 18
Study 32925959 — intervention group
Group type: EXPERIMENTAL
Intervention: longtail bike
Number of subjects: 18
Study 32925959 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional bike
Number of subjects: 18
Study 32925959 — intervention group
Group type: COMPARATOR
Intervention: Control (car use)
Number of subjects: 18
Study 34479835 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (400 mg/d)
Number of subjects: 160
Study 34479835 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/d)
Number of subjects: 160
Study 34479835 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and clonazepam
Number of subjects: 160
Study 32067256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (n = 26)
Number of subjects: 52
Study 32067256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26, control group)
Number of subjects: 52
Study 33919779 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal (CARB; 1 g/kg CHO)
Number of subjects: 17
Study 33919779 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal (PROTEIN; 0.45 g/kg protein + 0.24 g/kg fat)
Number of subjects: 17
Study 33919779 — intervention group
Group type: COMPARATOR
Intervention: Water (FASTED)
Number of subjects: 17
Study 33919779 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (CARB, PROTEIN, FASTED)
Number of subjects: 17
Study 34453570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application group (M-group)
Number of subjects: 82
Study 34453570 — intervention group
Group type: COMPARATOR
Intervention: Handout group (H-group)
Number of subjects: 82
Study 33607805 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliosis surgery and diaphragmatic breathing and pursed lip exercises (Group 1)
Number of subjects: 30
Study 33607805 — intervention group
Group type: COMPARATOR
Intervention: Scoliosis surgery (Group 2)
Number of subjects: 30
Study 32762224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent training
Number of subjects: 300
Study 32762224 — intervention group
Group type: COMPARATOR
Intervention: Routine aerobic exercise
Number of subjects: 300
Study 36051926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime combined with piperacillin
Number of subjects: 150
Study 36051926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 150
Study 36051926 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 150
Study 36051926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (Ceftazidime + Piperacillin)
Number of subjects: 150
Study 36051926 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 healthy subjects)
Number of subjects: 150
Study 33709483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis (BIA)
Number of subjects: 132
Study 33709483 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 132
Study 32161942 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 57
Study 32161942 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 57
Study 32161942 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT sampling
Number of subjects: 57
Study 32161942 — intervention group
Group type: COMPARATOR
Intervention: Referral-Only intervention
Number of subjects: 57
Study 36197880 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a dog
Number of subjects: 21
Study 36197880 — intervention group
Group type: COMPARATOR
Intervention: Plush animal (control)
Number of subjects: 21
Study 33754864 — intervention group
Group type: EXPERIMENTAL
Intervention: Conidial suspensions of L. biglobosa 'brassicae' and 'canadensis' (10 μL, 1 × 10^7 conidia mL‐1) inoculated on needle‐wounded cotyledons of B. napus cultivar Zhongshuang No. 9.
Number of subjects: 19
Study 33754864 — intervention group
Group type: COMPARATOR
Intervention: Water inoculation on needle‐wounded cotyledons (control group).
Number of subjects: 19
Study 36123106 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 67
Study 36123106 — intervention group
Group type: EXPERIMENTAL
Intervention: Community action planning process
Number of subjects: 67
Study 34280733 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca vaccine
Number of subjects: 1012
Study 34280733 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1012
Study 34280733 — intervention group
Group type: EXPERIMENTAL
Intervention: General population post vaccination
Number of subjects: 1012
Study 34280733 — intervention group
Group type: EXPERIMENTAL
Intervention: General population
Number of subjects: 1012
Study 34021092 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-change athletic cooling vest
Number of subjects: 0
Study 34021092 — intervention group
Group type: COMPARATOR
Intervention: Standardized training/playing ensemble (control)
Number of subjects: 0
Study 32558726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged suppressive valacyclovir
Number of subjects: 79
Study 32558726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 34487043 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-site rTMS (n=20)
Number of subjects: 20
Study 34487043 — intervention group
Group type: COMPARATOR
Intervention: Control-site rTMS (n=7)
Number of subjects: 20
Study 32183775 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital communication tool for non-German-speaking patients
Number of subjects: 3
Study 32183775 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (German-speaking patients)
Number of subjects: 3
Study 32183775 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (non-German-speaking patients treated without the tool)
Number of subjects: 3
Study 35594122 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational tool (MET)
Number of subjects: 380
Study 35594122 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 380
Study 34218184 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable HEPA filter air cleaners
Number of subjects: 480
Study 34218184 — intervention group
Group type: COMPARATOR
Intervention: No air cleaners (Control)
Number of subjects: 480
Study 36123113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) medication (Epidiolex)
Number of subjects: 80
Study 36123113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33905350 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 42
Study 33905350 — intervention group
Group type: COMPARATOR
Intervention: Family therapy as usual (FTAU)
Number of subjects: 42
Study 32734606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 9323
Study 32734606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9323
Study 32734606 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 9323
Study 33120482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal expansion suppository (150 mg) daily at night for 7 days
Number of subjects: 211
Study 33120482 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole vaginal tablet (500 mg) single dose
Number of subjects: 211
Study 36330106 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing delivered via instant messaging
Number of subjects: 60
Study 36330106 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation booklet
Number of subjects: 60
Study 33380165 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusion assessment method
Number of subjects: 141
Study 33380165 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria
Number of subjects: 141
Study 33380165 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 141
Study 33380165 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale
Number of subjects: 141
Study 33380165 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke-induced disorientation
Number of subjects: 141
Study 33380165 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect
Number of subjects: 141
Study 32339648 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib (10 mg/kg intravenously every 2 weeks plus 5 mg orally twice daily)
Number of subjects: 886
Study 32339648 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg orally once daily for 4 weeks)
Number of subjects: 886
Study 32339648 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 886
Study 32339648 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 886
Study 35244042 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐LRYNGO (channel-type video-laryngoscope with AI-based glottis guidance system)
Number of subjects: 30
Study 35244042 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30
Study 35244042 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath laryngoscope
Number of subjects: 30
Study 35244042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway-Scope
Number of subjects: 30
Study 34166117 — intervention group
Group type: EXPERIMENTAL
Intervention: Blepharoplasty with internal browpexy
Number of subjects: 62
Study 34166117 — intervention group
Group type: COMPARATOR
Intervention: Blepharoplasty alone (control)
Number of subjects: 62
Study 34127547 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed Diagnostic Opportunities (MDOs) identified through case note reviews
Number of subjects: 2057
Study 34127547 — intervention group
Group type: EXPERIMENTAL
Intervention: Contributing process breakdowns in MDOs
Number of subjects: 2057
Study 34127547 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe avoidable patient harm from MDOs
Number of subjects: 2057
Study 34127547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-reviewer agreement on MDOs
Number of subjects: 2057
Study 32115517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg once daily
Number of subjects: 30
Study 32115517 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 30
Study 36053447 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 137
Study 36053447 — intervention group
Group type: COMPARATOR
Intervention: Conventional Fluid Therapy (Control)
Number of subjects: 137
Study 34403892 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiatsu massage (three 5-minute periods with a 2-minute break)
Number of subjects: 68
Study 34403892 — intervention group
Group type: COMPARATOR
Intervention: Touch on the area considered for the massage (control group)
Number of subjects: 68
Study 36217159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (RAS)
Number of subjects: 6286
Study 36217159 — intervention group
Group type: COMPARATOR
Intervention: Post-referral parenteral antimalarials plus oral artemisinin-based combination therapy (ACT)
Number of subjects: 6286
Study 34100542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 111
Study 34100542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 32862264 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant oil (PO) - Linseed oil (LSO)
Number of subjects: 360
Study 32862264 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant oil (PO) - Corn oil (CO)
Number of subjects: 360
Study 32862264 — intervention group
Group type: COMPARATOR
Intervention: Control - Fish oil (FO)
Number of subjects: 360
Study 35998706 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal-telemonitoring group
Number of subjects: 168
Study 35998706 — intervention group
Group type: COMPARATOR
Intervention: Usual-CPAP-telemonitoring group
Number of subjects: 168
Study 35998706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168
Study 33632022 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 92
Study 33632022 — intervention group
Group type: COMPARATOR
Intervention: Healthy Dietary Advice (HDA)
Number of subjects: 92
Study 32278779 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled regimens aligning with GOLD recommendations
Number of subjects: 738
Study 32278779 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential overtreatment
Number of subjects: 738
Study 32278779 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment
Number of subjects: 738
Study 32278779 — intervention group
Group type: COMPARATOR
Intervention: Composite outcome (time to death or first hospitalization for COPD)
Number of subjects: 738
Study 35908345 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarettes (preference)
Number of subjects: 87
Study 35908345 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol cigarettes (preference)
Number of subjects: 87
Study 35908345 — intervention group
Group type: COMPARATOR
Intervention: Higher nicotine content cigarettes (NNC vs VLNC)
Number of subjects: 87
Study 35908345 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol preference
Number of subjects: 87
Study 33994285 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic support surface
Number of subjects: 72
Study 33994285 — intervention group
Group type: COMPARATOR
Intervention: Gel support surface
Number of subjects: 72
Study 33994285 — intervention group
Group type: COMPARATOR
Intervention: Standard operating table
Number of subjects: 72
Study 33530854 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia seeds (40 g/day for 12 weeks)
Number of subjects: 42
Study 33530854 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 42
Study 33843376 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 days a week for 10 weeks, 60-90 minutes each session)
Number of subjects: 23
Study 33843376 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 23
Study 33843376 — intervention group
Group type: COMPARATOR
Intervention: Control (no regular exercise)
Number of subjects: 23
Study 32250444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation device (NMES)
Number of subjects: 28
Study 32250444 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings
Number of subjects: 28
Study 34851445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine (T3, Tetronine®) 1 μg/kg-body weight/dose every 6 hours for 60 hours
Number of subjects: 120
Study 34851445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine (T3)
Number of subjects: 120
Study 34851445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine (T3) in low-risk patients (Aristotle score < 10.0)
Number of subjects: 120
Study 34851445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triiodothyronine (T3) in low-risk patients
Number of subjects: 120
Study 32878448 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-only weekly vouchers
Number of subjects: 359
Study 32878448 — intervention group
Group type: EXPERIMENTAL
Intervention: Household size effect
Number of subjects: 359
Study 33316626 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 1 g/d
Number of subjects: 61
Study 33316626 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 2 g/d
Number of subjects: 61
Study 33316626 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA 4 g/d
Number of subjects: 61
Study 33316626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33099633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) supplementation in AKI models (IRI)
Number of subjects: 2
Study 33099633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) supplementation in CKD models
Number of subjects: 2
Study 33099633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) supplementation in human kidney allograft biopsies
Number of subjects: 2
Study 33099633 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) supplementation in mice with UUO or chronic proteinuric glomerular disease
Number of subjects: 2
Study 32147519 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy hypofractionated radiation therapy (HFRT; 43.5 Gy in 15 fractions over 3 weeks)
Number of subjects: 598
Study 32147519 — intervention group
Group type: COMPARATOR
Intervention: Nadir-PLC/pre-PLC ratio <0.8
Number of subjects: 598
Study 32147519 — intervention group
Group type: COMPARATOR
Intervention: Nadir-PLC/pre-PLC ratio ≥0.8
Number of subjects: 598
Study 35685284 — intervention group
Group type: COMPARATOR
Intervention: normobaric hypoxia at FiO2 14.7% (NH15)
Number of subjects: 15
Study 35685284 — intervention group
Group type: COMPARATOR
Intervention: normobaric hypoxia at FiO2 12.5% (NH13)
Number of subjects: 15
Study 35685284 — intervention group
Group type: EXPERIMENTAL
Intervention: normobaric normoxia (NN)
Number of subjects: 15
Study 34068083 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-weekly BTA dosing
Number of subjects: 263
Study 34068083 — intervention group
Group type: COMPARATOR
Intervention: 4-weekly BTA dosing
Number of subjects: 263
Study 34068083 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation from 4-weekly to 12-weekly BTA
Number of subjects: 263
Study 33827649 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupoints (SA) group
Number of subjects: 90
Study 33827649 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐specific acupoints (NSA) group
Number of subjects: 90
Study 33827649 — intervention group
Group type: COMPARATOR
Intervention: Non‐acupoints (NA) group
Number of subjects: 90
Study 33827649 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SA, NSA, NA)
Number of subjects: 90
Study 32052923 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS-AE
Number of subjects: 69
Study 32052923 — intervention group
Group type: COMPARATOR
Intervention: ST
Number of subjects: 69
Study 33623999 — intervention group
Group type: EXPERIMENTAL
Intervention: EUROASPIRE Risk Model
Number of subjects: 12484
Study 32649327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-Beam CT (CBCT) imaging
Number of subjects: 87
Study 32649327 — intervention group
Group type: COMPARATOR
Intervention: Electromagnetic Navigation (EMN)
Number of subjects: 87
Study 32649327 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT with EMN
Number of subjects: 87
Study 32649327 — intervention group
Group type: COMPARATOR
Intervention: EMN with CBCT
Number of subjects: 87
Study 32649327 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic accuracy per patient
Number of subjects: 87
Study 35288545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic testing
Number of subjects: 0
Study 35288545 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 33454714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyrus PlasmaKinetic system
Number of subjects: 113
Study 33454714 — intervention group
Group type: COMPARATOR
Intervention: Olympus TURis system
Number of subjects: 113